Erie, CO, United States of America

Corrie Lynn Gallant-Behm

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Boulder, CO (US) (2016 - 2018)
  • Erie, CO (US) (2018 - 2019)

Company Filing History:


Years Active: 2016-2019

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Corrie Lynn Gallant-Behm: A Focus on miRNA Therapeutics

Introduction: Corrie Lynn Gallant-Behm, an accomplished inventor based in Erie, CO, has made significant contributions to the field of molecular therapeutics. With four patents to his name, his work revolves around the development of targeted treatments that leverage microRNA (miRNA) technology to promote healing and prevent fibrotic conditions.

Latest Patents: Gallant-Behm's latest innovations include patents focusing on miR-92 inhibitors and miR-29 mimics. The patent for "MiR-92 inhibitors and uses thereof" details a novel approach to inhibit the activity of miR-92 through oligonucleotide inhibitors. This invention outlines methods for evaluating the effectiveness of therapeutics aimed at enhancing wound healing by modulating miR-92 function. Additionally, the patent titled "miR-29 mimics and uses thereof" presents synthetic oligonucleotide mimetics of miR-29, which can be utilized in pharmaceutical compositions to treat conditions resulting from the dysregulation of extracellular matrix genes, particularly tissue fibrotic conditions.

Career Highlights: As a key member of Miragen Therapeutics, Inc., Gallant-Behm has played a pivotal role in advancing the company's mission to develop RNA-targeted therapies that address serious medical needs. His expertise in molecular biology and innovative approach have positioned him as a leader in the field of miRNA therapeutics.

Collaborations: Throughout his career, Gallant-Behm has worked alongside talented professionals such as Christina Marie Dalby and Rusty L Montgomery. These collaborations have contributed to the successful development and commercialization of groundbreaking therapeutic solutions.

Conclusion: Corrie Lynn Gallant-Behm's innovative work exemplifies the potential of microRNA therapeutics in addressing critical health issues. His contributions to the field through his patents not only enhance scientific understanding but also pave the way for new treatments that could significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…